Coherus Biosciences (CHRS)
NASDAQ:CHRS

Coherus Biosciences Stock Analysis & Ratings

Coherus Biosciences Stock Analysis Overview

Smart Score
4
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Coherus Biosciences stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

CHRS

CHRS Stock Stats

Previous Close$12.72
Open$12.77
Bid0 x 0
Ask0 x 0
Today’s Range$12.55 - $13.125
52-Week Range$12.21 - $22.22
Volume975.12K
Average Volume703.66K
Market Cap$966.73M
Beta0.92
P/E Ratio-4.0
EPS-3.13
Earnings DateMar 03, 2022

Company Description

Coherus Biosciences

Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
Sector
Healthcare
Industry
Biotechnology
CEO
Dennis M. Lanfear
Employees
334
Website
http://www.coherus.com
ISIN
US19249H1032
Address
333 Twin Dolphin Drive, Redwood City, CA, 94065, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

CHRS FAQ

What was Coherus Biosciences’s price range in the past 12 months?
Coherus Biosciences lowest stock price was $12.21 and its highest was $22.22 in the past 12 months.
    What is Coherus Biosciences’s market cap?
    Coherus Biosciences’s market cap is $966.73M.
      What is Coherus Biosciences’s price target?
      The average price target for Coherus Biosciences is $28.00. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $30.00 ,the lowest forecast is $22.00. The average price target represents 122.40% Increase from the current price of $12.59.
        What do analysts say about Coherus Biosciences?
        Coherus Biosciences’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
          When is Coherus Biosciences’s upcoming earnings report date?
          Coherus Biosciences’s upcoming earnings report date is Mar 03, 2022 which is in 39 days.
            How were Coherus Biosciences’s earnings last quarter?
            Coherus Biosciences released its earnings results on Nov 08, 2021. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.346 by -$0.144.
              Is Coherus Biosciences overvalued?
              According to Wall Street analysts Coherus Biosciences’s price is currently Undervalued.
                Does Coherus Biosciences pay dividends?
                Coherus Biosciences does not currently pay dividends.
                What is Coherus Biosciences’s EPS estimate?
                Coherus Biosciences’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Coherus Biosciences have?
                Coherus Biosciences has 76,790,000 shares outstanding.
                  What happened to Coherus Biosciences’s price movement after its last earnings report?
                  Coherus Biosciences reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.346. Following the earnings report the stock price went up 4.941%.
                    Which hedge fund is a major shareholder of Coherus Biosciences?
                    Among the largest hedge funds holding Coherus Biosciences’s share is Perceptive Advisors LLC. It holds Coherus Biosciences’s shares valued at 77M.

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis